3rd Quarter - Report

TIBER CREEK GROUP for TIBER CREEK HEALTH STRATEGIES, INC. (ON BEHALF OF NOVARTIS)

Firm
Client
Income
$60,000
Expenses
—

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Medicare/Medicaid MMM

Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169); Issues related to drug pricing; Issues related to the One Big Beautiful Bill Act (PL 119-21); Issues related to H.R. 1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act.

Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

LobbyistCovered position, as disclosed
JOHN MICHAEL GONZALEZ —
JONATHON JONES —
EMILY KIRLIN —
COREY MALMGREN —
ANDREW MCKECHNIE —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 1492 (119th), H.R. 1672 (119th)

Health Issues HCR

Issues related to drug pricing; Issues related to the One Big Beautiful Bill Act (PL 119-21); Issues related to 340B Drug Pricing Program; General intellectual property issues; Issues related to pharmacy benefit managers; Issues related to Most Favored Nation (MFN) policy.

Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

LobbyistCovered position, as disclosed
JOHN MICHAEL GONZALEZ —
JONATHON JONES —
EMILY KIRLIN —
COREY MALMGREN —
ANDREW MCKECHNIE —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Trade (domestic/foreign) TRD

Issues related to tariff policy and supply chain policy.

Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

LobbyistCovered position, as disclosed
JOHN MICHAEL GONZALEZ —
JONATHON JONES —
EMILY KIRLIN —
COREY MALMGREN —
ANDREW MCKECHNIE —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.